SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-017454
Filing Date
2023-05-04
Accepted
2023-05-04 07:05:24
Documents
13
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K stok-20230504.htm   iXBRL 8-K 55146
2 EX-99.1 stok-ex99_1.htm EX-99 280641
  Complete submission text file 0000950170-23-017454.txt   469865

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT stok-20230504_lab.xml EX-101.LAB 13350
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT stok-20230504.xsd EX-101.SCH 2496
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT stok-20230504_pre.xml EX-101.PRE 9858
7 EXTRACTED XBRL INSTANCE DOCUMENT stok-20230504_htm.xml XML 4701
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 23886396
SIC: 2834 Pharmaceutical Preparations